Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Urology

How Often Is Low-Risk Prostate Cancer Actively Monitored?

At a Glance

For low-risk prostate cancer, active surveillance usually includes PSA testing every 3–6 months, a prostate exam every 6–12 months, and a confirmatory biopsy within 6–12 months, followed by biopsies about every 2–3 years; your doctor adjusts the plan to your risk and test results.

In this answer

5 sections

01

Who is Eligible for Active Surveillance?

02

A Typical Monitoring Schedule

03

What Happens if My PSA Goes Up?

04

Outcomes: Is Active Surveillance Safe?

05

Active Surveillance vs. Watchful Waiting

For many men with favorable-risk prostate adenocarcinoma, active surveillance is the guideline-preferred approach [1]. Rather than rushing into surgery or radiation, this strategy uses a structured schedule of tests to monitor the cancer closely. A typical schedule includes a Prostate-Specific Antigen (PSA) blood test every 3 to 6 months, a digital rectal exam (DRE) every 6 to 12 months, and often a confirmatory biopsy within the first year, followed by periodic biopsies every 2 to 3 years [2][3]. The primary goal is to safely defer treatment—and avoid side effects like urinary or sexual dysfunction—while keeping the option to cure the cancer if tests show it is starting to grow [4][5].

Who is Eligible for Active Surveillance?

Active surveillance is frequently recommended for men with localized, low-risk prostate cancer, meaning the cancer is confined to the prostate (clinical stages cT1 to cT2a) [1][6]. Eligibility is typically based on several factors:

  • Grade Group 1 (Gleason 3+3=6): This is the lowest grade assigned to prostate cancer today. It means the cells look very close to normal and are usually slow-growing [7].
  • PSA Level and PSA Density: Doctors look for a PSA level generally below 10 ng/mL. They also calculate PSA density (your PSA divided by the size of your prostate) to ensure the PSA level is proportionate to your prostate size, rather than being driven by cancer [7][8].
  • Low Tumor Volume: Only a small amount of cancer is found on the biopsy (e.g., few positive cores, and only a small percentage of each core contains cancer) [8][9].
  • Favorable Grade Group 2: In carefully selected cases, men with Grade Group 2 (Gleason 3+4=7) may be eligible, provided they have a very low proportion of the more aggressive “pattern 4” cells and no highly adverse features (like cribriform or intraductal growth patterns) [10][11][12].

A Typical Monitoring Schedule

There is no single universal timetable; your specific schedule will be individualized based on your baseline risk, age, and initial biopsy quality [13]. However, a standard monitoring plan generally includes:

1. PSA Tests and Physical Exams

  • PSA Blood Test: Typically checked every 3 to 6 months.
  • Digital Rectal Exam (DRE): Your doctor checks your prostate for physical changes, usually every 6 to 12 months [2].

2. Prostate Biopsies

Biopsies provide the most definitive tissue evidence of whether the cancer’s grade has changed [10]. However, biopsies carry small risks, such as temporary bleeding, urinary difficulty, or infection [14].

  • Confirmatory Biopsy: Often done within the first 6 to 12 months. If your initial diagnosis was made using a high-quality MRI-targeted biopsy combined with systematic sampling, your doctor might choose to delay or skip this step [3][15].
  • Routine Repeat Biopsies: Generally scheduled every 2 to 3 years. These intervals may be adjusted based on your PSA trends and MRI results [2].

3. Multiparametric MRI (mpMRI)

Multiparametric MRI (mpMRI) is an advanced scan used to look for suspicious areas in the prostate [16]. If an MRI shows a suspicious lesion, your doctor can use it to guide the biopsy needle directly to that spot, alongside standard random (systematic) sampling [15]. While highly useful, a “clean” or stable MRI cannot perfectly rule out microscopic cancer growth, so it generally does not completely replace periodic routine biopsies [17][18].

4. Genomic Testing

Doctors can run genomic tests (analyzing the genes of the tumor tissue) to better understand how aggressively the cancer might behave [19]. Guidelines do not recommend these tests for everyone, but they can be helpful if your clinical findings are mixed and you are uncertain about choosing surveillance [1][20].

What Happens if My PSA Goes Up?

A temporary rise in PSA is very common and can be caused by non-cancer factors like a urinary tract infection, benign prostate enlargement, recent ejaculation, or inflammation. If your PSA rises, your doctor will likely repeat the test to confirm it and look for these common causes.

A rising PSA or a short PSA doubling time (how fast the PSA level doubles) should prompt a closer look—such as getting an MRI or another biopsy—but it should not automatically trigger you to undergo surgery or radiation [21][22].

The primary trigger for active treatment is biopsy-confirmed grade upgrading [10]. If a repeat biopsy finds that the cancer has evolved to a higher risk level (such as Grade Group 3 or a significant increase in tumor volume), you and your doctor will discuss transitioning to definitive treatment [23][14].

Outcomes: Is Active Surveillance Safe?

For appropriately selected men who stick to their monitoring schedule, active surveillance is highly effective at preserving quality of life while keeping the cancer in check. In long-term studies tracking favorable-risk patients, the 10- to 15-year prostate-cancer-specific survival rate is approximately 99% [24]. However, the risk is not completely zero, and missing appointments can undermine this safety.

Choosing surveillance does not mean you will never need treatment. In major cohort studies, roughly 50% of men transitioned to treatment (surgery or radiation) within 10 years [25][24]. This means that while half of the men safely deferred treatment for a decade or more, those who eventually needed treatment still maintained excellent long-term outcomes [26].

Active Surveillance vs. Watchful Waiting

These two strategies are often confused, but their goals are entirely different [4]:

  • Active Surveillance is a structured monitoring plan with curative intent. It is meant for men whose life expectancy is long enough that they would benefit from a cure if the cancer progresses [5].
  • Watchful Waiting is a less intensive, symptom-management approach. It typically avoids routine biopsies or MRIs. It is often recommended for older men or those with serious medical conditions who have a shorter life expectancy. The goal is to treat symptoms if they ever arise, rather than trying to cure the cancer [27][28].

Common questions in this guide

How often should I have PSA tests during active surveillance?
PSA is commonly checked every 3 to 6 months, although your doctor may adjust the timing based on your starting risk and PSA pattern. A digital rectal exam is often done every 6 to 12 months.
When is a confirmatory prostate biopsy usually done?
A confirmatory biopsy is often performed within 6 to 12 months after diagnosis. If the first biopsy used high-quality MRI-targeted and standard sampling, your doctor may delay or skip it; later biopsies are commonly repeated every 2 to 3 years.
Does a rising PSA mean I need surgery or radiation?
Not necessarily. A temporary PSA rise can come from infection, benign enlargement, recent ejaculation, or inflammation, so the test is often repeated; persistent changes may lead to MRI or biopsy, and treatment is usually based on biopsy evidence that the cancer has become higher risk.
Can a prostate MRI replace regular biopsies during surveillance?
MRI can find suspicious areas and help guide a targeted biopsy, but a stable or normal MRI cannot rule out all microscopic cancer. For that reason, MRI usually complements rather than replaces periodic biopsies.
How is active surveillance different from watchful waiting?
Active surveillance is a structured follow-up plan for men who may still benefit from cure if the cancer changes; it uses regular PSA tests and may include exams, MRI, and biopsies. Watchful waiting is less intensive and focuses on treating symptoms if they develop, often for older people or those with serious health conditions and limited life expectancy.
How safe is active surveillance for properly selected low-risk prostate cancer?
For appropriately selected men who follow monitoring, about 99% were alive without dying from prostate cancer 10 to 15 years later in long-term studies. Active surveillance does not mean treatment will never be needed; about half of men in major studies moved to surgery or radiation within 10 years, while long-term outcomes remained excellent.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What Do PI-RADS 3, 4, and 5 Mean on a Prostate MRI? What to Do After a Negative Prostate Biopsy With High PSA? How Long Is ADT With Radiation for Prostate Cancer? What Is the Next Step After a High PSA? Testing Path When Is PSMA PET/CT Needed for Prostate Cancer Staging?
Show more
How Are the Six Prostate Cancer Risk Groups Defined? Can Prostatitis, BPH, Sex, or Cycling Raise PSA Levels? Can You Have Prostate Cancer With a Negative MRI, High PSA? How Do Cribriform and IDC-P Affect Prostate Cancer Risk? Surgery or Radiation Better for High-Risk Prostate Cancer? Can a Second Review Change Your Prostate Cancer Grade? What Do T, N, and M Stages Mean in Prostate Cancer? Should I Get Genetic Testing After Prostate Cancer? How Do Age and Health Affect Prostate Cancer Treatment? When to Leave Active Surveillance for Prostate Cancer? Are Genomic Tests Useful for Prostate Cancer Decisions? Can Testosterone or Supplements Worsen Prostate Cancer? Why Are Prostate Biopsies Done? Risks and Methods Explained When Should I Start Prostate Cancer Screening If High Risk?

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific schedule do you recommend for my PSA tests, exams, MRIs, and biopsies?
  2. 2.Did my initial biopsy include MRI-targeted sampling, and do I need a confirmatory biopsy this year?
  3. 3.What is my exact clinical stage, PSA density, and Grade Group?
  4. 4.Are there any adverse features, like cribriform patterns, in my pathology report?
  5. 5.If my PSA goes up, what steps will we take before deciding on treatment?
  6. 6.What specific findings on a future biopsy or MRI would make you recommend surgery or radiation?

References

References (28)
  1. 1

    Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

    Chen RC, Rumble RB, Loblaw DA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(18)):2182-90 doi:10.1200/JCO.2015.65.7759.

    PMID: 26884580
  2. 2

    Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.

    Soeterik TFW, van Melick HHE, Dijksman LM, et al.

    European urology oncology 2019; (2(5)):483-489 doi:10.1016/j.euo.2019.01.010.

    PMID: 31411970
  3. 3

    Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.

    Kinsella N, Helleman J, Bruinsma S, et al.

    Translational andrology and urology 2018; (7(1)):83-97 doi:10.21037/tau.2017.12.24.

    PMID: 29594023
  4. 4

    Active surveillance for prostate cancer.

    Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, et al.

    International journal of urology : official journal of the Japanese Urological Association 2016; (23(3)):211-8 doi:10.1111/iju.13016.

    PMID: 26621054
  5. 5

    Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.

    Herden J, Weissbach L

    World journal of urology 2018; (36(3)):383-391 doi:10.1007/s00345-018-2175-0.

    PMID: 29330583
  6. 6

    Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.

    Leyh-Bannurah SR, Abou-Haidar H, Dell'Oglio P, et al.

    BJU international 2017; (119(5)):692-699 doi:10.1111/bju.13570.

    PMID: 27367469
  7. 7

    Pathological outcomes in men with prostate cancer who are eligible for active surveillance.

    Wang SC, Chen CC, Yang CK, et al.

    Journal of the Chinese Medical Association : JCMA 2018; (81(4)):348-351 doi:10.1016/j.jcma.2017.07.008.

    PMID: 28988599
  8. 8

    Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

    Loeb S, Folkvaljon Y, Curnyn C, et al.

    JAMA oncology 2017; (3(10)):1393-1398 doi:10.1001/jamaoncol.2016.3600.

    PMID: 27768168
  9. 9

    Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.

    Ouzzane A, Renard-Penna R, Marliere F, et al.

    The Journal of urology 2015; (194(2)):350-6.

    PMID: 25747105
  10. 10

    [Active surveillance of prostate cancer].

    Bolenz C, Grimm MO, Heidenreich A, et al.

    Urologie (Heidelberg, Germany) 2025; (64(6)):595-605 doi:10.1007/s00120-025-02555-z.

    PMID: 40111527
  11. 11

    Active surveillance for the management of localized prostate cancer: Guideline recommendations.

    Morash C, Tey R, Agbassi C, et al.

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2015; (9(5-6)):171-8 doi:10.5489/cuaj.2806.

    PMID: 26225165
  12. 12

    Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database.

    Jung G, Kim JK, Jeon SS, et al.

    The world journal of men's health 2023; (41(1)):110-118 doi:10.5534/wjmh.210163.

    PMID: 35118841
  13. 13

    Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.

    Luckenbaugh AN, Auffenberg GB, Hawken SR, et al.

    The Journal of urology 2017; (197(3 Pt 1)):621-626 doi:10.1016/j.juro.2016.09.071.

    PMID: 27663459
  14. 14

    Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer.

    Deville C, Kamran SC, Morgan SC, et al.

    Practical radiation oncology 2024; (14(1)):47-56 doi:10.1016/j.prro.2023.09.007.

    PMID: 38182303
  15. 15

    Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.

    Schoots IG, Nieboer D, Giganti F, et al.

    BJU international 2018; (122(6)):946-958 doi:10.1111/bju.14358.

    PMID: 29679430
  16. 16

    MRI and active surveillance: thoughts from across the pond.

    Campbell RA, Wood A, Schwen Z, et al.

    European radiology 2025; (35(4)):2157-2169 doi:10.1007/s00330-024-10866-6.

    PMID: 39266769
  17. 17

    Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.

    Chappidi MR, Newcomb LF, Zheng Y, et al.

    The Journal of urology 2025; (214(3)):251-258 doi:10.1097/JU.0000000000004592.

    PMID: 40305682
  18. 18

    Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.

    Chesnut GT, Vertosick EA, Benfante N, et al.

    European urology 2020; (77(4)):501-507 doi:10.1016/j.eururo.2019.12.009.

    PMID: 31874726
  19. 19

    The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.

    Cooperberg MR, Erho N, Chan JM, et al.

    European urology 2018; (74(4)):444-452 doi:10.1016/j.eururo.2018.05.014.

    PMID: 29853306
  20. 20

    A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance.

    Merriel SWD, Moon D, Dundee P, et al.

    BMC urology 2021; (21(1)):18 doi:10.1186/s12894-021-00789-5.

    PMID: 33541309
  21. 21

    Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.

    Bokhorst LP, Alberts AR, Rannikko A, et al.

    European urology 2015; (68(5)):814-21.

    PMID: 26138043
  22. 22

    Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

    Cooperberg MR, Brooks JD, Faino AV, et al.

    European urology 2018; (74(2)):211-217 doi:10.1016/j.eururo.2018.01.017.

    PMID: 29433975
  23. 23

    A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.

    Bokhorst LP, Valdagni R, Rannikko A, et al.

    European urology 2016; (70(6)):954-960 doi:10.1016/j.eururo.2016.06.007.

    PMID: 27329565
  24. 24

    Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

    Tosoian JJ, Mamawala M, Epstein JI, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(30)):3379-85 doi:10.1200/JCO.2015.62.5764.

    PMID: 26324359
  25. 25

    Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.

    Newcomb LF, Schenk JM, Zheng Y, et al.

    JAMA 2024; (331(24)):2084-2093 doi:10.1001/jama.2024.6695.

    PMID: 38814624
  26. 26

    The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience.

    Paudel R, Madan R, Qi J, et al.

    The Journal of urology 2023; (209(1)):170-179 doi:10.1097/JU.0000000000003012.

    PMID: 36265120
  27. 27

    Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.

    Van Hemelrijck M, Garmo H, Lindhagen L, et al.

    European urology 2017; (72(4)):534-541 doi:10.1016/j.eururo.2016.10.031.

    PMID: 27816297
  28. 28

    When and How Should Active Surveillance for Prostate Cancer be De-Escalated?

    Rajwa P, Sprenkle PC, Leapman MS

    European urology focus 2021; (7(2)):297-300 doi:10.1016/j.euf.2020.01.001.

    PMID: 32019719

This page explains a typical active-surveillance schedule for low-risk prostate cancer for informational purposes only and does not constitute medical advice. Your urologist or cancer care team should tailor testing and treatment decisions to your health and biopsy results.